GlassScriptPhysician profile
Kaylin Garnett
NPI 1609396324
$9,166.26
in general payments reported to CMS, 2019-2025
24 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,290 · 2022: $1,316 · 2023: $2,129 · 2024: $2,128 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,097 · Education: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,097.18 |
| Education | $463.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,449.11 | 2021-2025 | |
| Janssen Biotech, INC. | $1,592.33 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $689.21 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $659.77 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $494.48 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $482.79 | 2021-2025 | |
| Lilly USA, LLC | $475.77 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $421.75 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $363.30 | 2021-2022 | |
| Amgen INC. | $336.15 | 2022-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $208.17 | 2021-2025 | |
| Leo Pharma INC. | $187.51 | 2021-2025 | Adbry, Anzupgo |
| Organon LLC | $157.66 | 2025 | Vtama |
| Incyte Corporation | $151.03 | 2021-2024 | Opzelura |
| Pfizer INC. | $144.88 | 2021-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $75.19 | 2021-2025 | Nemluvio, Oracea, Epsolay |
| Mayne Pharma Commercial LLC | $72.13 | 2025 | |
| Vyne Pharmaceuticals INC. | $45.85 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.94 | 2021-2025 | Cabtreo |
| Ucb, INC. | $37.71 | 2023 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $33.01 | 2024-2025 | Zoryve |
| Abiomed | $19.82 | 2025 | |
| Botanix Sb INC | $15.55 | 2025 | Sofdra |
| Epi Health, LLC | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylin Garnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.